International multicenter randomized, placebo-controlled phase III clinical trial of β-D-mannuronic acid in rheumatoid arthritis patients.
Zahra RezaieyazdiAbid FarooqiHossein Soleymani-SalehabadiArman AhmadzadehMona AslaniSaiedeh OmidianArezoo SadoughiZohreh VahidiMandana KhodashahiShazia ZamurradSeyed Shahabeddin Mortazavi-JahromiHossein FallahzadehMostafa HosseiniZahra AghazadehParvin EkhtiariHidenori MatsuoBernd H A RehmSalvatore CuzzocreaAntimo D'AnielloAbbas MirshafieyPublished in: Inflammopharmacology (2019)
The results of this multinational, phase III clinical trial provided a potent evidence base for the use of β-D-mannuronic acid as a new highly safe and efficient drug in the treatment of RA.
Keyphrases
- phase iii
- double blind
- placebo controlled
- clinical trial
- rheumatoid arthritis patients
- open label
- phase ii
- disease activity
- study protocol
- rheumatoid arthritis
- phase ii study
- systemic lupus erythematosus
- emergency department
- ankylosing spondylitis
- squamous cell carcinoma
- adverse drug
- combination therapy
- locally advanced
- interstitial lung disease
- radiation therapy
- cross sectional
- smoking cessation